Cyclacel appoints Dr Nicholas Bacopoulos to Board
This article was originally published in Scrip
Cyclacel Pharmaceuticals, a US biopharmaceutical company discovering, developing and commercialising mechanism-targeted drugs to treat cancer and other serious disorders, has appointed Dr Nicholas Bacopoulos to its board of directors. Dr Bacopoulos's previous leadership roles include CEO and president of Aton Pharma (a company subsequently acquired by Merck), where he led the development of Zolinza. He was formerly president and head of R&D at OSI Pharmaceuticals, where he was involved with the global development of Tarceva, approved for the treatment of non-small cell lung and pancreatic cancers.